Pharmacovigilance in Covid-19 vaccines

¹ Hospital of specialties Tangiers, Morocco.
² Laboratory of Genetic and Biometry, Faculty of Sciences, Ibn Tofail University, Kenitra, Morocco.
³ Laboratory of Botany, Biotechnologies and plants Protection, Faculty of Sciences, Ibn Tofail University, Kenitra, Morocco.
⁴ Antipoison and Pharmacovigilance Center, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

^* Corresponding author: hananebahouq@yahoo.fr

Abstract

The ongoing pandemic coronavirus disease of 2019 (COVID-19), originated from Wuhan, China, has caused universal challenging and threatening with considerable health impact and economic losses. Therefore, vaccination, as preventive and protective medical countermeasure, remains an excellent issue for reducing morbidity and mortality of this emerging infectious disease. As of April 2021 and by Emergency Use Authorization (EUA) process, 16 vaccines were authorized by at least one national regulatory authority for public use: two Ribonucleic Acid (RNA) vaccines (Pfizer–BioNTech and Moderna), seven conventional inactivated vaccines (BBIBP-CorV manufactured by Siinopharm, CoronaVac, Covaxin, WIBP-CorV, CoviVac, Minhai-Kangtai and QazVac), five viral vector vaccines (Sputnik Light, Sputnik V, Oxford–AstraZeneca, Convidecia, and Johnson & Johnson) and two protein subunit vaccines (EpiVacCorona and RBD-Dimer). As other countries, Morocco has established an anti-COVID-19 vaccine strategy in order to effectively contribute to the monitoring of vaccine safety supported by the national platform health vigilance and regulated by the National Anti-Poison and Pharmacovigilance Center (CAPM). In this review, we recorded the main current developed COVID-19 vaccines and discussed pharmacovigilance strategies and tools related safety and tolerability of those therapies. In parallel, a review of the Moroccan experience in this field is also conducted.